Second PSMA PET Scan Changes Treatment for Nearly Half of Prostate Cancer Patients

New research published in The Journal of Nuclear Medicine reveals that a second prostate-specific membrane antigen (PSMA) PET scan changed treatment plans for nearly 50% of patients whose initial scan was negative. These repeat scans detected both localized and distant disease that was missed on the first examination. This finding underscores the importance of repeat imaging in prostate cancer management, particularly for patients with negative initial results. The discovery could significantly improve outcomes by identifying cancer that requires treatment intervention, offering patients more accurate staging and appropriate therapeutic options.